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Summary.-Levels of misonidazole in human tumours, normal tissues and blood
have been measured in patients given a 1g oral dose ofdrug before surgery or biopsy.
The results show that50-700 of the blood level was found in a wide range of tumours
and that similar levels were found in adjacent normal tissues.
Good penetration of drug was achieved within tumours, and up to 90-100% of the
blood level was found in the necrotic cyst fluid at the centre of some tumours. CSF
studies showed free diffusion into the CNS, which was confirmed by finding50-70O%
of the blood level within brain tumours. A delay of passage of drugs into the CSF was
noted, which was not found for drug diffusion into bile and saliva.
EXTENSIVE in vitro and in vivo animal
experiments have confirmed the effective-
ness of misonidazole (MIS) as a sensitizer
of hypoxic tumour cells to radiation and
shown that it produces an improvement in
local tumour cure rates when given before
radiation (Denekamp & Fowler, 1978).
The animal work has shown that the
effectiveness of MIS is closely related to
the concentration of drug achieved in the
tumour and to the timing of radiation
after drug administration (McNally et al.,
1978). Unfortunately, however, the mouse
is a poor pharmacokinetic model for man
because of its short half-life for MIS, and
human data are therefore essential.
Early Phase I studies in man (Gray et
al., 1976; Urtasun et al., 1977) have shown
that MIS gets into tumours, but there is
little information on the penetration ofthe
drug in different tumour types nor on
penetration into the central nervous sys-
tem (CNS). Because of this, uncertain
extrapolations are made from blood levels
to tissue levels. There is also a lack ofdata
on the distribution of drug in normal
tissues or within a tumour. The present
investigation has therefore sought to gain
more information in patients with a
variety of tumours, so that this can be
used to plan optimum combinations of
drug and radiation.
MATERIALS AND METHODS
Drug levels were measured in tumours and
normal tissues by giving a standard 1 g oral
dose of MIS at least 4 h before surgery to
patients having operations or biopsies for
cancer. Results in normal tissues were ob-
tained from patients with Hodgkin's disease
undergoing laparotomy. Apart from a small
amount ofskin and muscle, the tissue samples
were taken from tissues that were to be re-
moved in the normal course of the operation,
and informed consent was given by all
patients. All biopsies were obtained 4-6 h
after oral administration of the drug, and at
the same time a sample of venous blood was
taken, to obtain simultaneous measurements
ofMIS concentration in blood and tissue.
Serial studies on the cerebrospinal fluid
(CSF) were performed in patients with acute
leukaemia who were receiving weekly lumbar
punctures (i.p.) as part of their CNS pro-
phylactic treatment. In one series the patients
were asked to take 1 g of MIS at different
intervals before each i.p. A specimen of blood
* To whom requests for reprints should be sent. Present address: Regional Radiotherapy Centre, Cookridge
Ho,spital, Leeds, England.
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was also taken at the time of l.p. so that in
each patient a graph of blood and CSF levels
ofMIS against time could be drawn.
In another series the interval was kept
constant at 6 h and the dose of drug varied
before each l.p. so that a graph of MIS level
in blood and CSF against oral dose could be
drawn.
Serial studies in saliva, bile and ascitic
fluid were obtained after a single oral dose
ofdrug followed by regular sampling ofblood
and relevant body fluid. In the case of bile,
this was obtained from a T tube inserted into
the common bile duct after exploration for
stones.
Distribution ofthedrugwithintumourswas
assessed bydividing the tumour specimeninto
several pieces and analysing each separately.
Samples of adjacent normal tissues were also
taken.
The total nitroimidazole in blood, CSF,
saliva and all other fluid samples was meas-
ured by differential pulse polarography
(Princeton Applied Research, 174a Polaro-
graphic analyser) according to the method of
Kane (1961). The concentration of MIS was
measured in homogenized tissue samples,
either by gas-liquid chromatography using
the method of Flockhart et al. (1978) or by
high-pressure liquid chromatography accord-
ing to the method of Workman et al. (1978).
All samples were either frozen or analysed
within 2 h of biopsy. In all cases results are
expressed as MIS concentration in ,ug/ml
for fluids and ,ug/g for tissues. In order to
assess penetration and diffusion of the drug,
results are also expressed as a ratio of the
MIS level in tissue or body fluid to the simul-
taneously obtained blood level.
RESULTS
Table I shows the levels of MIS meas-
ured in breast cancer, gynaecological
cancer, urological tumours and benign
thyroid cysts. The breast-cancer results
show that the mean tumour level after a
1 g oral dose in 9 patients was 12-4 ,ug/g
+ 4-2 with a range of 6-5-19-8 ,g/g. The
mean tumour/blood ratio for these cases
was 0-56 + 0-12 (range 0.38-0-70). For 9
gynaecological cancers the mean tumour
level of MIS was 19-7 ,ug/g ± 5-5 (range
11-1-28) and the mean tumour/blood
ratio 0-77 + 0-20 (range 0-43-1-03). Many
of these tumours were necrotic, and 3 had
received previous external beam radio-
therapy. In spite of this, however, the
drug levels were similar to those in other
tissues.
The tumour/blood ratios in urological
cancer show a range from 0-28 to 0-58 but
in 2 cases only a trace ofdrug was detected
for reasons that are unclear, though blood
level was also very low in one of these. On
the whole, these levels appear to be rather
lower than those at other sites, though
numbers are too small to draw definite
conclusions.
Two cases of benign thyroid cyst were
studied because they seemed to provide a
good model of an encapsulated tumour
with a necrotic centre. The results show
that there had been free diffusion through
the fibrous capsule, producing levels in the
cyst fluid comparable to those in the
blood. Only 50% of the blood level, how-
ever, was recovered in the necrotic tissue
in the centre of the cyst and 25% in the
fibrous cyst wall.
In 5 of the cases of breast cancer, mul-
tiple biopsies were obtained both from the
tumour and from the adjacent normal
tissues. In all cases it was noted that
60-70% of the blood level was found in
areas of solid tumour tissue, but that
levels were lower in those areas which were
a mixture of tumour and fat. The drug
levels in normal skin adjacent to the
tumour were similar to those within the
tumour, indicating good diffusion across
the tissues, but the levels in subcutaneous
fat were invariably low and confirmed the
impression that the relatively low levels in
some parts of the tumour were due to the
presence of fat and not to poor diffusion.
Areas of overt necrosis are relatively un-
common in operable breast cancer, so an
assessment of such areas was not possible.
Fig. 1 shows an example of one of the
cases, in which a 4-cm tumour was divided
into 12 pieces and each analysed separ-
ately.
Multiple biopsies were also obtained
from a cystectomy performed in a case of
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TABLE I.-Misontdazole levels in human tumours 4-6 h after Ig oral dose
Tumour type and stage
Ca Breast T2
, Tla
, T4c
, T2
, T4b
, T2b
,, T3b
T2a
2° node in axilla
Ca cervix IIB
Cone biopsy for dysplasia
*Ca cervix with vaginal recurrence
Ca cervix III
*Ca uterus, recurrence
Ca colon with vaginal recurrence
Ca vagina
Ca cervix IIIB
*Ca cervix IIIB
Ca bladder T3
Ca prostate T2M1
Ca bladder T3
Ca bladder T4a
Ca bladder T3
Benign thyroid cyst-
fluid
fibrous cyst wall
necrotic centre
fluid
fibrous cyst wall
necrotic centre I
MIS level
Blood Tumour
,ug/ml ug/g
21 13-1
10 6-5
12 8-2
27 12-2
24 11*7
32 19-8
45 17-0
21 14-1
22 9-6
26
22
26
26
27
27
26
25
24
19
20
9
32
27
19
25
23-8
17-1
20-6
20-7
28-0
11-7
22-9
21-7
11-1
Trace
11-5
Trace
8-9
11*7
18-0
4-6
7-8
25-0
10-1
14-0
Tumour/blood
ratio
070
0-65
0-68
0*45
0 49
0-62
0-38
0-67
0*44
0-92
0-78
0-79
0*79
1-03
043
0-88
0*87
0-46
low
0 57
low
0-28
045
0.95
0-25
0-41 J
1-00)
0-25
0 58J
Time
(h)
41
5
41
61
51
61
41
6
43
5
51
61
41:
41 5
4
10
5
* Previous external beam radiotherapy.
bladder cancer and showed, similarly,
50% of the blood level in the bladder
mucosa, the perivesical muscle and the
ureter, but only 15% in the perivesical fat
(Table II).
The access of drug into the CNS was
TABLE II.-Distribution ofmisonidazole in
a bladder cancer
Tissue
Blood
MIS level Tissue/blood
,uglg or ,Lg/ml ratio
27-0
46-0
12-1 0-45
11-7 0-43
11-6 043
14-6 0*54
4-2 0.15
0 lcm 2cm 3cm 4cm Urine
Tumour
FIG. 1.-Distribution of MIS within a breast Normal mucosa
tumour. The figure in each square repre- Normal vesical muscle
sents the level ofdrug (,g/g) in that part of Normal ureter
the tumour. Normal perivesical fat
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FIG. 2.-MIS levels in blood ancl CSF after Ig oral dose.
assessed in 3 ways. Fig. 2 shows the uptake
of drug into the blood and CSF in 5 cases
after a -g oral dose. The graph shows that
the level of MIS in the blood attained a
peak at 2-3 h, whereas comparable levels
were not achieved in the CSF until 5-6 h.
The graph indicates a delay of drug entry
into the CSF but shows that 80-1000% of
36
32
28
1-.24 -1
20
w 16
0
x 12
8
4
0
.0
Dose of Misonidazole (g)
Fie. 3. Blood ard CSF concentration of
MIS with increasing oral dose in onre
patient.
the maximum blood level may eventually
be obtained in the CSF.
Fig. 3 shows the effect in one patient-
of increasing the oral dose of MIS on the
blood and CSF concentration. In this case
all drug levels were measured 6 h after an
oral dose of MIS, and the dose of drug in-
creased before each of 4 l.p.s. The graph
shows a linear response both for blood and
CSF levels from 0'5 g up to 2 g. Within
this range, therefore, there was no absorp-
tion plateau in CSF levels. It is interesting
to note that the blood and CSF levels
were almost identical at 6 h, which tends
to confirm the previous observation of a
delay before CSF levels equal those in the
blood.
Penetration of the drug into brain
tumours was assessed by giving 1 g of
MIS 4 h before craniotomy at which
samples of tumour, normal brain and
tumour cyst fluid were taken. The results
are shown in Table III. These show that
the levels in brain tumours were similar to
those in other tissues (mean 15 7 ,ug/g:
range 14-2-16.6) and that up to 90%0 of
the blood level could be recovered in the
cyst fluid from the centre of the necrotic
tumours. In those cases in which samples
were also taken from the junction of the
6 7
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TABLE III.-Misonidazole levels in brain tumours 5-7 h after 1 g oral dose
MIS levels in ,tg/
Tumour type
Cystic glioblastoma
Cystic glioblastoma
Glioblastoma
Medulloblastoma
Cystic glioblastoma
Cystic glioblastoma
* Tissue/blood ratio.
la
-
Cu
:0 I
a
N
co
n
Blood
17
24
30
27
16
9
Tumour
cyst fluid
12 (0-70)*
22 (0 92)
6 (0.38)
2 (0 22)
Tumour Junction
tissue tumour-normal
16-6 (0 69)
16-3 (0 54)
14-2 (0 52)
Normal Time
brain (h)
i3
15-3 (0.64) 14-5 (0 60) 7
51
15-8 (0 58) 16-6 (0-61) 6
51
5
tumour and normal brain, and from nor-
mal brain itself, there was again good
diffusion of the drug with levels com-
parable to those within the tumour.
Because of the time taken to perform the
craniotomy the brain-tumour samples
were obtained after a longer delay than
the other tumours and normal tissue (i.e.
5-7 h rather than 4-6 h).
Diffusion of the drug throughout the
body was studied in a number of normal
tissues and also in saliva, bile and ascitic
Blood Muscle Skin Appdx Spleen Fat
FIG. 4.- Mean MIS levels (+s.d.) in normi
tissues (6 patients each received 1 g MI
4-6 h pre-operatively).
bA
-4
4)
0.
AL)
CO
Liver filuid. F.ig. 4 shows the mean blood and
tissue levels in 6 patients who had
IS laparotomies for Hodgkin's disease. 50%
of the blood level was found in skin and
- Blood
- - -Ascites
Time (h)
FIG. 5.- M1IS levels in blood, bile, saliva and ascitic fluid in 3 patients.
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muscle. Thespleenandappendix contained
250% ofthebloodlevel, andfatwasagainlow
with only 19% ofblood level. A surprising
feature of these patients was that no MIS
was found in the liver. In no case was
more than a faint trace of drug detected,
and neither was desmethyl misonidazole
(Ro-05-9963), which is a product of
aerobic metabolism of MIS.
Fig. 5 shows examples of drug concen-
tration/time curves for saliva, bile and
ascitic fluid in 3 patients. These demon-
strated a free diffusion into these fluids
but, unlike the CSF, there was no delay in
the peak compared with that in the blood.
The saliva level reached 100% of that in
blood and total nitromidazole level in bile
was 810% of blood level. The patient with
ascites had 105% ofthe blood level present
in the ascitic fluid at 3 and 5 h after
administration ofMIS.
DISCUSSION
These results confirm the early pharma-
cokinetic data of Gray et al. (1976) and
show that MIS is a freely diffusible sub-
stance which penetrates well into tumours.
In this study a nominal dose of 1 g ofMIS
was given, but similar diffusion most
probably occurs at higher doses. This is
certainly true of blood, in which there is a
linear relationship between oral dose and
blood level up to 10 g (Gray et al., 1976)
which has also been shown in this study
for CSF up to 2 g.
Comparison of results in tumours and
normal tissues show that there is no
appreciable difference between the 2,
and that even in cases of cervical cancer
which were necrotic and had received ex-
ternal beam therapy there was good pene-
tration of the drug. The multiple biopsies
performed within individual tumours also
show that the drug was present not only
at the periphery ofthe tumour, but also in
the centre. Some variation of drug levels
was found, but this was clearly related to
the amount of fat in the tissue and not to
the position of the tissue in relation to the
centre ofthe tumour.
In spite of the fact that MIS has lipo-
philic properties, its octanol-water par-
tition coefficient is only 0 43, suggesting
that in a blood/fat milieuthe concentration
in blood is likely to be higher than in fat,
even if free diffusion occurs.
MIS entered the CSF readily and
80-100% of the blood level was achieved.
It was also shown to penetrate freely into
the centre of necrotic tumours, as shown
by the high levels of drug in the cyst fluid
from these tumours. The levels of drug in
the normal brain and in the tumour tissue
were also high, and demonstrate good
diffusion throughout the CNS. Although
the drug entered the CNS freely, there was
a delay in reaching its peak compared
with that in the blood.
For non-CNS tumours, the blood data
suggest that it may be acceptable to
irradiate 2--3 h after an oral dose ofMIS,
but for brain tumours the CSF data in-
dicate that 4 h is probably the minimum
interval which should be allowed, and 5 or
6 h might be better.
The surprising failure to demonstrate
MIS in the liver demands an explanation.
One possibility is that metabolism in the
liver was so rapid that the drug was all
broken down. It is unlikely that the
metabolism occurred in the normal aero-
bic state, however, as it would be unusual
for such rapid metabolism to be associated
with a half-life of 10-12 h and one would
also expect to find elevated levels of
desmethyl misonidazole (Ro-05-9963),
which is a product of aerobic metabolism.
If rapid metabolism is the cause it seems
more likely that this occurred under
anaerobic conditions after the removal of
the liver from the body. At this point the
tissues rapidly become hypoxic, and it is
possible that MIS underwent anaerobic
metabolism to compounds that could not
be measured. This may also occur to a
lesser extent in other tissues, and subse-
quent studies (M. R. Smith, personal com-
munication, 1978) have shown that up to
20% of drug may be broken down within
2 h of biopsy. It is, however, particularly
marked in the liver, which has abundant
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enzyme capacity for such degradation of
the drug.
Although MIS appeared to pass freely
into most tissues and into body fluids, it
was nevertheless common to find no more
than 50-70%o of the blood level in the
tissues, whereas 80-100% was usually
found in saliva, CSF and bile, and even at
the centre of cystic tumours such as the
thyroid and brain, where 70-10000 of the
blood level was found. One must wonder
whether the lower levels in tissue are a
true reflection of the actual drug level or
the result of other factors which do not
operate in fluid samples. The influence of
fat in the tissue sample has already been
noted and is probably the cause of some
low levels. The presence of abundant non-
cellular material in the sample may also
result in low overall levels, whereas the
actual intracellular fluid level may, in fact,
be as high as that in blood. It is also pos-
sible that some loss of drug has occurred
by anaerobic metabolism while the tissue
has been anoxic. During the study there
was often a delay of 30-120 min before
analysis of tissue samples, and a certain
amount of breakdown of MIS may well
have occurred in this time. When blood or
CSF samples have been left for up to 24 h,
there is no drug degradation, and it seems
that tissue enzymes may be required for
this degradation (Pedersen et al., 1979).
Further work is required to confirm these
factors, but it seems likely that the true
level of MIS within tumours is a little
higher than those presented here.
These results confirm that MIS does
indeed diffuse freely and rapidly through
the body, that it penetrates to the centre
of necrotic tumours and that it enters the
CNS readily. They provide further en-
couragement for its use as a radiosensitizer
and for the institution ofcontrolled clinical
trials, which are necessary to demonstrate
its effectiveness in man.
The help and encouragement of Professor G. E.
Adams is gratefully acknowledged.
Misonidazole was supplied by Roche Products
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